The original success of Sildenafil undeniably transformed the medication landscape, but betting in companies primarily reliant on unbranded versions presents a complex picture. Although early returns were substantial, the expiration of patents and the appearance of cheaper alternatives have eroded market share. Consequently, a thorough evaluation o